Epigenomics completed its U.S. clinical validation study for its second-generation colorectal cancer blood test Epi proColon, according to a news release.
The study found Epi proColon detected 68 percent of colorectal cancer cases while correctly identifying 80 percent of the patients free of disease. The company will also complete a head-to-head comparative study with fecal immunochemical testing. Data from both studies will be part of the devices' premarket approval process, which the company said should be complete in 2012.
Related Articles on Colon Cancer:
Half of Colorectal Cancer Cases Could be Prevented by Lifestyle Changes
Everist Genomics Discovers Genes Responsible for Recurrence of Colorectal Cancer
Water Infusion for Cecal Intubation Increases Patient Tolerance, but not Intubation in Unsedated Colonoscopy
The study found Epi proColon detected 68 percent of colorectal cancer cases while correctly identifying 80 percent of the patients free of disease. The company will also complete a head-to-head comparative study with fecal immunochemical testing. Data from both studies will be part of the devices' premarket approval process, which the company said should be complete in 2012.
Related Articles on Colon Cancer:
Half of Colorectal Cancer Cases Could be Prevented by Lifestyle Changes
Everist Genomics Discovers Genes Responsible for Recurrence of Colorectal Cancer
Water Infusion for Cecal Intubation Increases Patient Tolerance, but not Intubation in Unsedated Colonoscopy